Drug Trial Radar · NCT07351734
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of JKN2403 in COPD
Last checked: Nov 19, 2026Latest source record: Jan 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Nov 6, 2025
Primary completion
Sep 30, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Joincare Pharmaceutical Group Industry Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if drug JKN2403 works to treat moderate-to-severe COPD in adults. It will also learn about the safety and pharmacokinetic characteristics of drug JKN2403. The main questions it aims to answer are: Does drug JKN2403 reduce the incidence of AECOPD or improve the quality of life or alleviate symptoms related to COPD? Researchers will compare drug JKN2403 to a placebo (a look-alike substance that contains no drug) to see if drug JKN2403 works to treat moderate-to-severe COPD. Participants will: Take drug JKN2403 or a placebo every day for 24 weeks Visit the clinic once every four weeks for checkups and tests Keep a diary of their symptoms and the number of times they use a rescue inhaler
Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
Interventions
JKN2403 TabletsDrug
JKN2403 Tablets once daily orally, for 24 weeks
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The annualized incidence rate of moderate to severe AECOPDTime frame: at 24 months
- The duration from the first administration to the first occurrence of moderate to severe AECOPDTime frame: at 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.